Analyst Price Targets — NKTR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 11:51 am | Martin Fan | Wedbush | $80.00 | $81.89 | TheFly | Nektar price target lowered to $80 from $95 at Wedbush |
| May 8, 2026 11:07 am | Yasmeen Rahimi | Piper Sandler | $192.00 | $83.37 | TheFly | Nektar price target raised to $192 from $105 at Piper Sandler |
| April 21, 2026 12:50 pm | — | Wedbush | $95.00 | $101.64 | TheFly | Nektar price target raised to $95 from $70 at Wedbush |
| April 20, 2026 2:33 pm | — | H.C. Wainwright | $185.00 | $106.75 | TheFly | Nektar price target raised to $185 from $165 at H.C. Wainwright |
| March 13, 2026 4:39 pm | Jay Olson | Oppenheimer | $140.00 | $73.27 | StreetInsider | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer |
| February 10, 2026 5:17 pm | — | BTIG | $151.00 | $52.00 | TheFly | Nektar price target raised to $151 from $118 at BTIG |
| February 10, 2026 2:16 pm | — | H.C. Wainwright | $165.00 | $52.62 | TheFly | Nektar price target raised to $165 from $135 at H.C. Wainwright |
| January 26, 2026 1:56 pm | Yasmeen Rahimi | Piper Sandler | $105.00 | $36.35 | StreetInsider | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' |
| December 16, 2025 5:48 pm | — | H.C. Wainwright | $135.00 | $51.17 | TheFly | Nektar price target raised to $135 from $120 at H.C. Wainwright |
| December 16, 2025 4:08 pm | Jay Olson | Oppenheimer | $115.00 | $50.43 | TheFly | Nektar price target raised to $115 from $98 at Oppenheimer |
Latest News for NKTR
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025…
Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted average price of $60.75 per share. This sale represented 26.64% of his direct common stock holdings and reduced his direct position from 75,073 to 55,045 shares.
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of…
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NKTR.
U.S. House Trading
No House trades found for NKTR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.